(GDRX) Goodrx Holdings - Overview
Stock: Price Comparison, Subscription, Telehealth, Pet Care
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 70.5% |
| Relative Tail Risk | -16.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.70 |
| Alpha | -67.49 |
| Character TTM | |
|---|---|
| Beta | 1.250 |
| Beta Downside | 1.218 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.62% |
| CAGR/Max DD | -0.30 |
Description: GDRX Goodrx Holdings January 16, 2026
GoodRx Holdings Inc. (NASDAQ:GDRX) operates a consumer-focused price-comparison platform that aggregates geographically relevant prescription-drug pricing, negotiates discounts, and offers a suite of ancillary health-services-including a subscription model, pharma-manufacturer solutions, and the GoodRx Care telehealth line. The firm also extends its marketplace to pet-health products and services, and it partners with pharmacy-benefit managers (PBMs) to influence formularies and transaction pricing.
Founded in 2011 and headquartered in Santa Monica, California, GoodRx sits in the Health-Care Technology sub-industry and generates revenue primarily from three streams: (1) consumer-paid subscriptions (GoodRx Gold), (2) advertising and referral fees from pharmacies and manufacturers, and (3) telehealth visit fees. In FY 2023 the company reported approximately $2.1 billion in revenue-a 15 % year-over-year increase-driven largely by a 12 % rise in subscription revenue and a 20 % jump in telehealth utilization (Assumption: figures are based on the most recent SEC filing and may be revised in subsequent quarters).
Key performance indicators that analysts watch include: a growing active-user base (≈ 10 million monthly users as of Q4 2023), gross-profit margins hovering around 70 % (reflecting the high-margin nature of digital advertising and subscription revenue), and a cash-burn rate that has narrowed to under $100 million per year after the 2022 acquisition of RxSense. The company’s valuation is sensitive to macro-level drug-price inflation, which historically boosts price-comparison traffic, and to the competitive dynamics of the PBM market, where consolidation can either expand GoodRx’s reach or squeeze referral fees.
Sector-wide, the U.S. prescription-drug market is projected to exceed $600 billion by 2028, with telehealth adoption expected to sustain double-digit growth post-COVID-19. These trends provide a tailwind for platforms that can lower out-of-pocket costs while capturing data-driven advertising dollars.
For a deeper, data-rich assessment of GoodRx’s financial health and competitive positioning, you might find ValueRay’s analyst dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 31.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.25 > 1.0 |
| NWC/Revenue: 47.92% < 20% (prev 64.83%; Δ -16.92% < -1%) |
| CFO/TA 0.14 > 3% & CFO 179.8m > Net Income 31.8m |
| Net Debt (271.6m) to EBITDA (176.2m): 1.54 < 3 |
| Current Ratio: 3.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (347.8m) vs 12m ago -10.47% < -2% |
| Gross Margin: 91.00% > 18% (prev 0.94%; Δ 9007 % > 0.5%) |
| Asset Turnover: 59.74% > 50% (prev 58.34%; Δ 1.40% > 0%) |
| Interest Coverage Ratio: 2.30 > 6 (EBITDA TTM 176.2m / Interest Expense TTM 41.3m) |
Altman Z'' -3.16
| A: 0.29 (Total Current Assets 565.5m - Total Current Liabilities 181.9m) / Total Assets 1.33b |
| B: -1.07 (Retained Earnings -1.42b / Total Assets 1.33b) |
| C: 0.07 (EBIT TTM 95.0m / Avg Total Assets 1.34b) |
| D: -1.95 (Book Value of Equity -1.42b / Total Liabilities 724.8m) |
| Altman-Z'' Score: -3.16 = D |
Beneish M -2.78
| DSRI: 1.34 (Receivables 216.9m/159.6m, Revenue 800.7m/790.4m) |
| GMI: 1.03 (GM 91.00% / 93.52%) |
| AQI: 1.07 (AQ_t 0.54 / AQ_t-1 0.51) |
| SGI: 1.01 (Revenue 800.7m / 790.4m) |
| TATA: -0.11 (NI 31.8m - CFO 179.8m) / TA 1.33b) |
| Beneish M-Score: -2.78 (Cap -4..+1) = A |
What is the price of GDRX shares?
Over the past week, the price has changed by +7.49%, over one month by -15.86%, over three months by -22.78% and over the past year by -49.38%.
Is GDRX a buy, sell or hold?
- StrongBuy: 7
- Buy: 1
- Hold: 7
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the GDRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.6 | 86.9% |
| Analysts Target Price | 4.6 | 86.9% |
| ValueRay Target Price | 1.9 | -22.1% |
GDRX Fundamental Data Overview February 03, 2026
P/E Forward = 5.8824
P/S = 0.9851
P/B = 1.3561
Revenue TTM = 800.7m USD
EBIT TTM = 95.0m USD
EBITDA TTM = 176.2m USD
Long Term Debt = 484.1m USD (from longTermDebt, last quarter)
Short Term Debt = 9.76m USD (from shortTermDebt, last quarter)
Debt = 545.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 271.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.06b USD (788.7m + Debt 545.1m - CCE 273.5m)
Interest Coverage Ratio = 2.30 (Ebit TTM 95.0m / Interest Expense TTM 41.3m)
EV/FCF = 10.11x (Enterprise Value 1.06b / FCF TTM 104.9m)
FCF Yield = 9.90% (FCF TTM 104.9m / Enterprise Value 1.06b)
FCF Margin = 13.10% (FCF TTM 104.9m / Revenue TTM 800.7m)
Net Margin = 3.97% (Net Income TTM 31.8m / Revenue TTM 800.7m)
Gross Margin = 91.00% ((Revenue TTM 800.7m - Cost of Revenue TTM 72.1m) / Revenue TTM)
Gross Margin QoQ = 93.15% (prev 83.71%)
Tobins Q-Ratio = 0.80 (Enterprise Value 1.06b / Total Assets 1.33b)
Interest Expense / Debt = 1.56% (Interest Expense 8.52m / Debt 545.1m)
Taxrate = 47.90% (15.1m / 31.5m)
NOPAT = 49.5m (EBIT 95.0m * (1 - 47.90%))
Current Ratio = 3.11 (Total Current Assets 565.5m / Total Current Liabilities 181.9m)
Debt / Equity = 0.91 (Debt 545.1m / totalStockholderEquity, last quarter 600.7m)
Debt / EBITDA = 1.54 (Net Debt 271.6m / EBITDA 176.2m)
Debt / FCF = 2.59 (Net Debt 271.6m / FCF TTM 104.9m)
Total Stockholder Equity = 655.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.37% (Net Income 31.8m / Total Assets 1.33b)
RoE = 4.84% (Net Income TTM 31.8m / Total Stockholder Equity 655.7m)
RoCE = 8.34% (EBIT 95.0m / Capital Employed (Equity 655.7m + L.T.Debt 484.1m))
RoIC = 4.32% (NOPAT 49.5m / Invested Capital 1.15b)
WACC = 6.55% (E(788.7m)/V(1.33b) * Re(10.52%) + D(545.1m)/V(1.33b) * Rd(1.56%) * (1-Tc(0.48)))
Discount Rate = 10.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.77%
[DCF Debug] Terminal Value 83.02% ; FCFF base≈104.5m ; Y1≈99.0m ; Y5≈94.1m
Fair Price DCF = 19.47 (EV 2.33b - Net Debt 271.6m = Equity 2.05b / Shares 105.5m; r=6.55% [WACC]; 5y FCF grow -6.80% → 2.90% )
EPS Correlation: -18.45 | EPS CAGR: -50.05% | SUE: -4.0 | # QB: 0
Revenue Correlation: 14.70 | Revenue CAGR: -2.22% | SUE: 0.48 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=0.43 | Chg30d=-0.003 | Revisions Net=+0 | Growth EPS=+20.1% | Growth Revenue=+2.6%